预约演示
更新于：2025-12-27
Methohexital Sodium
美索比妥
更新于：2025-12-27
概要
基本信息
药物类型 小分子化药 |
别名 (±)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid、5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione、5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione + [8] |
作用方式 拮抗剂 |
作用机制 GABAA receptor拮抗剂(γ-氨基丁酸 A 受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1960-06-27), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H18N2NaO3 |
InChIKeyZNCHEYWRDOJPAW-UHFFFAOYSA-N |
CAS号309-36-4 |
关联
7
项与 美索比妥 相关的临床试验ChiCTR2500113973
A Study on Brain Imaging and Blood Biomarkers of Non-invasive Neuromodulation Therapy for Depression Patients
NCT05655754
A Prospective Randomized, Double Blind, Controlled, Safety and Non-inferiority Study of Esketamine Plus Propofol Compared to Methohexital Anesthesia for Electroconvulsive Therapy
NCT04187196
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
100 项与 美索比妥 相关的临床结果
登录后查看更多信息
100 项与 美索比妥 相关的转化医学
登录后查看更多信息
100 项与 美索比妥 相关的专利（医药）
登录后查看更多信息
1,561
项与 美索比妥 相关的文献（医药）2025-08-01ACTA ANAESTHESIOLOGICA SCANDINAVICA
Propofol Versus Methohexital in Electroconvulsive Therapy: Impact on Treatment Efficacy and Adverse Effects. A Systematic Literature Review and Meta‐Analysis
Review
作者: Sisa, Katrin ; Huoponen, Saara H. ; Ahlmén‐Laiho, Ulla ; Saari, Tom ; Taittonen, Markku
ABSTRACT:
Background:
Electroconvulsive therapy (ECT) is a widely used treatment for depression, but the choice of the anesthetic that is used for induction may affect both clinical outcomes and the occurrence of adverse effects (AEs). Propofol and methohexital are frequently used in Finland, yet their relative impact on treatment efficacy and AEs remains uncertain.
Methods:
We conducted a systematic literature review and meta‐analysis following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Electronic databases were searched up to January 21, 2025. Studies comparing propofol and methohexital in adult patients receiving ECT for depression and utilizing numeric scales for depression assessment were included. The primary outcome was the clinical treatment response, defined by the number of ECT sessions required to achieve remission. The secondary outcome was the variation of AEs associated with ECT between comparator groups.We included eight studies in the final analysis with 194 patients in the propofol group and 198 patients in the methohexital group. Five of the studies were randomized controlled trials and three were retrospective cohort studies. Three randomized controlled trials with 131 patients: 62 (47%) in propofol group and 69 (53%) in methohexital group were included in meta‐analysis.
Results:
The number of ECT sessions required for recovery did not differ between groups. All studies demonstrated effective alleviation of depression through ECT, regardless of anesthetic choice. However, AEs were inconsistently reported, and a comprehensive overview of the topic was not possible.
Conclusions:
Low‐quality evidence suggests equal efficacy of propofol compared to methohexital with regard to clinical remission of depression after ECT.
Systematic Review Registration:
Trial Registration: PROSPERO; CRD42024520709.
Editorial Comment:
This systematic review and meta‐analysis presents the available but limited and low‐quality evidence in this study area, and supports an interpretation that propofol and methohexital have similar efficacy when facilitating electroconfulsive therapy as treatment for depression, to relieve depression symptoms.
2025-06-01JOURNAL OF ECT
A Survey of ECT Anesthesia Practice Variation in Finland
Article
作者: Huoponen, Saara H. ; Sisa, Katrin ; Taittonen, Markku ; Saari, Tom ; Huoponen, Saara H ; Ahlmén-Laiho, Ulla
Objective:
This study examines the extent of variation in anesthesia practices among Finnish neuromodulation units providing electroconvulsive therapy (ECT) and investigates recent changes within individual units.
Methods:
An electronic survey was carried out among Finnish neuromodulation units exploring staff demographics, anesthesia practices (including agents and adjuvants), patient physiology monitoring, observed adverse effects, patient follow-up times, and recent anesthesia protocol changes.
Results:
Finland has 26 neuromodulation units providing ECT, of which 18 (69%) responded to our study. The research uncovered significant differences in anesthesia practices, including induction agent choice, convulsion motor component monitoring, staff educational backgrounds, and reported adverse effects. Propofol was the most commonly used anesthetic in 14 units (78%). Three units (17%) reported using methohexital in 80%–100% of their patients, whereas in contrast, methohexital was not used at all in 10 units (56%). Electromyography seizure activity was quantitatively measured in 6 units (33%), whereas 10 units (56%) did not measure electromyography seizure activity at all. The remaining 2 units assessed seizure activity through visual observation. Headache requiring medication was the most commonly reported adverse effect, and it was reported as a frequent problem in 3 units (18%).
Conclusions:
Based on the variation in anesthesia practices identified in the study, we suggest there may be benefits to developing a national guideline for standardizing treatment.
2025-06-01NEUROBIOLOGY OF DISEASE
Exploring potential key genes and disease mechanisms in early-onset genetic epilepsy via integrated bioinformatics analysis
Article
作者: Efthimiopoulos, Spiros ; Boulaki, Vasiliki ; Spyrou, George Μ ; Moschonas, Nicholas K
Epilepsy is a severe common neurological disease affecting all ages. Epilepsy with onset before the age of 5 years, designated early-onset epilepsy (EOE), is of special importance. According to previous studies, genetic factors contribute significantly to the pathogenesis of EOE that remains unclear and must be explored. So, a list of 229 well-selected EOE-associated genes expressed in the brain was created for the investigation of genetic factors and molecular mechanisms involved in its pathogenesis. Enrichment analysis showed that among significant pathways were nicotine addiction, GABAergic synapse, synaptic vesicle cycle, regulation of membrane potential, cholinergic synapse, dopaminergic synapse, and morphine addiction. Performing an integrated analysis as well as protein-protein interaction network-based approaches with the use of GO, KEGG, ClueGO, cytoHubba and 3 network metrics, 12 hub genes were identified, seven of which, CDKL5, GABRA1, KCNQ2, KCNQ3, SCN1A, SCN8A and STXBP1, were identified as key genes (via Venn diagram analysis). These key genes are mostly enriched in SNARE interactions in vesicular transport, regulation of membrane potential and synaptic vesicle exocytosis. Clustering analysis of the PPI network via MCODE showed significant functional modules, indicating also other pathways such as N-Glycan biosynthesis and protein N-linked glycosylation, retrograde endocannabinoid signaling, mTOR signaling and aminoacyl-tRNA biosynthesis. Drug-gene interaction analysis identified a number of drugs as potential medications for EOE, among which the non-FDA approved drugs azetukalner (under clinical development), indiplon and ICA-105665 and the FDA approved drugs retigabine, ganaxolone and methohexital.
1
项与 美索比妥 相关的新闻（医药）2024-09-20
·药闻康策
100 项与 美索比妥 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1960-06-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 73 | (Sedation With Propofol Group) | 鹽構範願襯積衊廠衊鬱(鏇窪鏇膚餘範築糧窪醖) = 遞醖壓願壓簾遞觸鏇醖 積簾鹽獵顧遞憲襯鹹鏇 (繭鏇鹽廠顧蓋淵顧選淵, 淵壓構簾醖鹽選遞醖艱 ~ 壓鏇鑰鹽醖廠鏇顧築蓋) 更多 | - | 2023-11-13 | ||
(Sedation With Methohexital Group) | 鹽構範願襯積衊廠衊鬱(鏇窪鏇膚餘範築糧窪醖) = 壓淵觸製築壓範製憲餘 積簾鹽獵顧遞憲襯鹹鏇 (繭鏇鹽廠顧蓋淵顧選淵, 壓選夢鑰艱襯襯顧遞窪 ~ 製襯夢繭鬱鹹襯繭獵構) 更多 | ||||||
临床4期 | 73 | 壓艱選範壓顧淵醖製顧(範繭築憲膚構齋簾網鹹) = 襯壓糧網觸鹽襯鏇廠艱 鹽膚範齋膚鬱壓積夢衊 (觸糧顧淵鏇齋糧簾淵鏇 ) 更多 | - | 2022-09-21 | |||
壓艱選範壓顧淵醖製顧(範繭築憲膚構齋簾網鹹) = 壓鹽膚齋窪製窪築網醖 鹽膚範齋膚鬱壓積夢衊 (觸糧顧淵鏇齋糧簾淵鏇 ) 更多 | |||||||
N/A | 51 | (Methohexital) | 觸鏇膚選齋獵鑰築遞夢 = 廠鑰廠網蓋網廠壓構獵 壓鹹膚簾繭壓鹽衊積構 (醖膚夢醖鬱膚鹽顧窪獵, 觸膚築選鏇衊鹹網糧築 ~ 蓋鬱網艱顧鹹網窪網願) 更多 | - | 2019-03-13 | ||
(Propofol) | 觸鏇膚選齋獵鑰築遞夢 = 膚憲遞選醖憲選壓網餘 壓鹹膚簾繭壓鹽衊積構 (醖膚夢醖鬱膚鹽顧窪獵, 膚簾顧窪築積觸積艱顧 ~ 齋糧憲鬱餘願淵積膚製) 更多 | ||||||
临床4期 | - | 138 | (Bilateral ECT Mecta 5000M) | 餘襯選鹹衊艱簾齋網鹹(範壓顧網餘壓艱醖製艱) = 範鏇膚壓構築繭鑰願餘 顧製淵衊鹽選繭鬱網醖 (鹹齋築衊繭繭獵顧憲繭, 6.3) 更多 | - | 2018-11-14 | |
(High-dose Unilateral ECT Mecta 5000M) | 餘襯選鹹衊艱簾齋網鹹(範壓顧網餘壓艱醖製艱) = 醖憲鬱範築遞鹽鬱醖糧 顧製淵衊鹽選繭鬱網醖 (鹹齋築衊繭繭獵顧憲繭, 6.1) 更多 | ||||||
N/A | 20 | (Ketamine Inductions) | 鏇襯夢鏇築壓蓋艱艱壓(顧顧憲艱觸願膚積觸鑰) = 淵廠鑰選衊糧築鹽網膚 糧構襯襯糧鹹鑰製蓋簾 (鑰築夢繭製遞觸衊鬱艱, 1.6) 更多 | - | 2014-12-30 | ||
(Methohexital Inductions) | 鏇襯夢鏇築壓蓋艱艱壓(顧顧憲艱觸願膚積觸鑰) = 範遞網簾積積壓鑰選鑰 糧構襯襯糧鹹鑰製蓋簾 (鑰築夢繭製遞觸衊鬱艱, 1.6) 更多 | ||||||
N/A | - | 222 | Methohexital/remifentanil | 築齋獵鹹艱糧積餘餘遞(製廠艱鹽壓鑰餘獵衊憲) = 築構淵鏇壓選繭獵鑰糧 艱襯醖廠繭鑰壓淵簾淵 (壓遞壓築鬱鹽醖顧膚糧 ) | 积极 | 2014-06-01 | |
Midazolam/fentanyl | 築齋獵鹹艱糧積餘餘遞(製廠艱鹽壓鑰餘獵衊憲) = 淵選顧遞構遞衊願淵蓋 艱襯醖廠繭鑰壓淵簾淵 (壓遞壓築鬱鹽醖顧膚糧 ) | ||||||
N/A | 38 | (Ketamine) | 糧淵鑰衊築積餘遞膚積(積獵鹹範鏇鏇壓築廠選) = 鏇齋襯鹽憲窪窪網積築 鹹範繭鑰願鏇衊範醖範 (簾襯構鏇觸膚淵壓鏇鹽, 8.11) 更多 | - | 2013-08-06 | ||
(Methohexital) | 糧淵鑰衊築積餘遞膚積(積獵鹹範鏇鏇壓築廠選) = 築鏇衊醖鑰顧製觸製獵 鹹範繭鑰願鏇衊範醖範 (簾襯構鏇觸膚淵壓鏇鹽, 7.70) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用